Atara seeks new CEO as Isaac Ciechanover exits; AstraZeneca's Mark Mallon tapped to replace Peter Hecht at Ironwood
→ In an abrupt departure, Isaac Ciechanover is stepping down from Atara Biotherapeutics $ATRA, the T cell therapy company that he founded in 2012 in honor of his mother. The South San Francisco biotech gave no reason for this change, which will take place by June 30, offering only the standard thank you and the vision for its pipeline of off-the-shelf CAR-T programs, allied with prominent investigators around the country.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
